186 related articles for article (PubMed ID: 34259028)
1. Durable complete remission of leptomeningeal melanoma by intrathecal methotrexate maintained with systemic ipilimumab.
Dietrich C; Salzmann M; Steinbrecher A; Herbst R; Hassel JC
Immunotherapy; 2021 Sep; 13(13):1079-1083. PubMed ID: 34259028
[TBL] [Abstract][Full Text] [Related]
2. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.
Geukes Foppen MH; Brandsma D; Blank CU; van Thienen JV; Haanen JB; Boogerd W
Ann Oncol; 2016 Jun; 27(6):1138-1142. PubMed ID: 26961150
[TBL] [Abstract][Full Text] [Related]
3. Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab.
Krueger O; Eisenburger R; Tasdogan A; Zimmer L; Livingstone E; Hadaschik E; Theurer S; Brodin B; Schadendorf D; Ugurel S
Front Immunol; 2024; 15():1369190. PubMed ID: 38807589
[TBL] [Abstract][Full Text] [Related]
4. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases.
Prakadan SM; Alvarez-Breckenridge CA; Markson SC; Kim AE; Klein RH; Nayyar N; Navia AW; Kuter BM; Kolb KE; Bihun I; Mora JL; Bertalan MS; Shaw B; White M; Kaplan A; Stocking JH; Wadsworth MH; Lee EQ; Chukwueke U; Wang N; Subramanian M; Rotem D; Cahill DP; Adalsteinsson VA; Miller JW; Sullivan RJ; Carter SL; Brastianos PK; Shalek AK
Nat Commun; 2021 Oct; 12(1):5955. PubMed ID: 34642316
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy.
Plaquevent M; Greliak A; Pinard C; Duval-Modeste AB; Joly P
Melanoma Res; 2019 Jun; 29(3):311-312. PubMed ID: 31026247
[TBL] [Abstract][Full Text] [Related]
6. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
Chorti E; Kebir S; Ahmed MS; Keyvani K; Umutlu L; Kanaki T; Zaremba A; Reinboldt-Jockenhoefer F; Knispel S; Gratsias E; Roesch A; Ugurel S; Scheffler B; Schadendorf D; Livingstone E; Meier F; Glas M; Zimmer L
Eur J Cancer; 2021 May; 148():395-404. PubMed ID: 33789203
[TBL] [Abstract][Full Text] [Related]
7. Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.
Haymaker C; Johnson DH; Murthy R; Bentebibel SE; Uemura MI; Hudgens CW; Safa H; James M; Andtbacka RHI; Johnson DB; Shaheen M; Davies MA; Rahimian S; Chunduru SK; Milton DR; Tetzlaff MT; Overwijk WW; Hwu P; Gabrail N; Agrawal S; Doolittle G; Puzanov I; Markowitz J; Bernatchez C; Diab A
Cancer Discov; 2021 Aug; 11(8):1996-2013. PubMed ID: 33707233
[TBL] [Abstract][Full Text] [Related]
8. The Role of Immune Checkpoint Inhibitors in Leptomeningeal Disease: A Systematic Review.
Palmisciano P; Haider AS; Nwagwu CD; Wahood W; Yu K; Ene CI; O'Brien BJ; Aoun SG; Cohen-Gadol AA; El Ahmadieh TY
Anticancer Res; 2021 Nov; 41(11):5333-5342. PubMed ID: 34732403
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
Stemmler HJ; Mengele K; Schmitt M; Harbeck N; Laessig D; Herrmann KA; Schaffer P; Heinemann V
Anticancer Drugs; 2008 Sep; 19(8):832-6. PubMed ID: 18690096
[TBL] [Abstract][Full Text] [Related]
10. Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
Day F; Kumar M; Fenton L; Gedye C
J Immunother; 2017 Jan; 40(1):36-38. PubMed ID: 27684455
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.
Glantz MJ; Jaeckle KA; Chamberlain MC; Phuphanich S; Recht L; Swinnen LJ; Maria B; LaFollette S; Schumann GB; Cole BF; Howell SB
Clin Cancer Res; 1999 Nov; 5(11):3394-402. PubMed ID: 10589750
[TBL] [Abstract][Full Text] [Related]
12. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
[TBL] [Abstract][Full Text] [Related]
13. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
15. Aggressive treatment with complete remission in primary diffuse leptomeningeal gliomatosis--a case report.
Beauchesne P; Pialat J; Duthel R; Barral FG; Clavreul G; Schmitt T; Laurent B
J Neurooncol; 1998 Apr; 37(2):161-7. PubMed ID: 9524095
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer leptomeningeal metastasis: the results of combined treatment and the comparison of methotrexate and liposomal cytarabine as intra-cerebrospinal fluid chemotherapy.
Niwińska A; Rudnicka H; Murawska M
Clin Breast Cancer; 2015 Feb; 15(1):66-72. PubMed ID: 25287959
[TBL] [Abstract][Full Text] [Related]
17. Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma.
Piña Y; Yadugiri S; Yeboa DN; Ferguson SD; Forsyth PA; Oliva ICG
Curr Oncol Rep; 2022 Jan; 24(1):43-54. PubMed ID: 35059999
[TBL] [Abstract][Full Text] [Related]
18. The Abscopal Effect in the Era of Checkpoint Inhibitors.
Kodet O; Němejcova K; Strnadová K; Havlínová A; Dundr P; Krajsová I; Štork J; Smetana K; Lacina L
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281259
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab.
Cafuir L; Lawson D; Desai N; Kesner V; Voloschin A
J Immunother Cancer; 2018 Jan; 6(1):11. PubMed ID: 29382383
[TBL] [Abstract][Full Text] [Related]
20. Management of leptomeningeal malignancy.
Pentheroudakis G; Pavlidis N
Expert Opin Pharmacother; 2005 Jun; 6(7):1115-25. PubMed ID: 15957966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
